Does HDL (ApoA-1) by itself play a major causal role in heart disease?
The answer from randomized controlled trials in humans is likely NO.
ApoA-1 is the main protein component of HDL in blood. Many studies have shown an association between lower levels of ApoA-1 (HDL) and higher risk of heart disease. The question is whether or not this association is actually causal?
Three major clinical trials testing drugs designed to raise HDL and apolipoprotein A-I (ApoA-I) levels in an attempt to reduce cardiovascular disease failed:
- ILLUMINATE Trial (torcetrapib)
Torcetrapib raised ApoA-I and HDL cholesterol levels substantially.
However, the trial was terminated early due to increased risk of cardiovascular events and mortality in the treatment group.
- dal-OUTCOMES Trial (dalcetrapib)
Dalcetrapib modestly raised ApoA-I and HDL-C levels by 30%.
But it did not reduce the risk of cardiovascular death, heart attack, or stroke compared to placebo.
- ACCELERATE Trial (evacetrapib)
Evacetrapib raised ApoA-I levels by over 100%. However, it did not significantly reduce major adverse cardiovascular events compared to placebo.
The trial was terminated early.
Other major trials also failed:
It’s not just the three CETP inhibitors mentioned above that have failed. Large trials that raised HDL and ApoA-1 by adding fibrates or niacin to standard of care failed.
Large trials of direct ApoA-1 therapies have also failed, e.g. CSL112. The recent failure of CSL112 in phase 3 was probably the nail in the coffin for ApoA-1 as directly causal. They literally gave the patients native ApoA-1 isolated from human plasma (CSL112) and it still failed.
↪ CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause
The same result occurs in Mendelian randomization studies. Genes that predispose people to higher HDL or ApoA-1 (without increasing insulin sensitivity) do not lower lifetime risk.
Summary:
Interventions to raise ApoA-1 and HDL have repeatedly failed to improve clinical outcomes in high-risk patient populations. The same result occurs in Mendelian randomization studies. This likely refutes the hypothesis that simply increasing circulating ApoA-I or HDL levels is sufficient by itself for cardiovascular risk reduction.
A possible explanation for the inverse association of ApoA-1 with heart disease is that ApoA-1 is an indirect marker (or proxy) for insulin sensitivity— and it is actually insulin sensitivity that is causal, as opposed to ApoA-1 itself. Higher levels of ApoA-1 likely reflect better insulin sensitivity, and thus lower risk for heart disease. Interventions that raise ApoA-1 or HDL without improving insulin sensitivity (like the drugs used in the clinical trials discussed above) are unlikely to lower risk for heart disease.
#hdlHD #tghdlratioHD #insulinresistanceHD #apoa1HD #cetpinhibitorHD #csl112HD #fibratesHD #niacinHD #vitaminb3HD
